VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2020 | GU update: ESMO 2020

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain summarizes the data for genitourinary cancer presented at ESMO 2020. Firstly, Dr Grande discusses the results of a Phase III DANUBE trial (NCT02516241) which investigated the use of durvalumab and durvalumab plus tremelimumab vs standard-of-care (SoC) chemotherapy (CT) in patients with stage IV urothelial carcinoma (UC). The KEYNOTE-361 (NCT02853305) Phase III trial which investigated the use of pembrolizumab with or without CT vs CT alone in advanced UC. Both trials failed to meet the primary endpoints of improving overall survival (OS). Secondly, Dr Grande discusses the results of a Phase III CheckMate 9ER trial (NCT03141177) which investigated the use of nivolumab combined with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma. Nivolumab combined with cabozantinib improved OS and progression-free survival (PFS) compared with sunitinib. Finally, Dr Grande addresses two new Phase III trials, the PROfound trial (NCT02987543) and the IPATential 150 trial (NCT03072238). The PROfound trial investigated the use of olaparib vs enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Patients with mCRPC and HRR alterations with prior new hormonal agent (NHA) treatment, olaparib improved radiographic progression-free survival (rPFS) and overall response rate (ORR). The IPATential 150 trial investigated the use of ipatasertib plus abiraterone and prednisone/prednisolone in mCRPC. This IPATential 150 study met its co-primary endpoint of rPFS in patients treated with Ipat plus abi and prednisone/prednisolone plus placebo. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter